首页> Molecular therapy : the journal of the American Society of Gene Therapy> Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4<sup>+</sup> myasthenia gravis.

Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4<sup>+</sup> myasthenia gravis.

导出 OA

翻译打印收藏纠错

第一作者： Stefanie,Schreiber

第一单位： Department of Neurology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. Electronic address: stefanie.schreiber@med.ovgu.de.

作者： Stefanie,Schreiber ^[1] ; Marwa,Al-Dubai ^[2] ; Stefan,Vielhaber ^[2] ; Lora,Lefterova ^[2] ; Sascha,Dietrich ^[3] ; Tobias,Ruck ^[4] ; Sven,Meuth ^[4] ; Denise,Walther ^[5] ; Dimitrios,Mougiakakos ^[6]

作者单位： Department of Neurology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. Electronic address: stefanie.schreiber@med.ovgu.de. ^[1] Department of Neurology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. ^[2] Department of Hematology and Oncology, University Hospital Düsseldorf and Center for Integrated Oncology Aachen Bonn Cologne, 40225 Düsseldorf, Germany. ^[3] Department of Neurology, University Hospital and Medical Faculty Düsseldorf, Heinrich Heine University Duesseldorf, 40225 Duesseldorf, Germany. ^[4] Department of Hematology, Oncology, and Cell Therapy, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. ^[5] Department of Hematology, Oncology, and Cell Therapy, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany. Electronic address: dimitrios.mougiakakos@med.ovgu.de. ^[6]

关键词 B cell depletion BCMA T cell engager autoimmune disorder immune reset immunotherapy myasthenia gravis plasma cells